Background: Bosentan is associated with adverse hepatic effects. To minimize such risk, regulators implemented risk minimization measures (RMMs), including testing for liver injury biomarkers (alanine and aspartate transaminase and bilirubin) prior to therapy initiation and monthly throughout therapy. This study aimed to examine the adherence to hepatic monitoring requirements.
Research Design And Methods: This retrospective cohort study collected data about bosentan new-users from the Real-world Evidence Research Network from 2016 to 2022. We ascertained hepatic tests from laboratory files. Adherence to RMM definition was performing the required tests within 90 days before initiation and categorized adherence to monthly testing requirement based on the expected number of tests throughout therapy as low (<50%), moderate (50-74%), and high (≥75%).
Results: One hundred patients entered the study cohort and 71% were females, with a median age of 25 years. Adherence to testing prior to bosentan initiation was 60%. Adherence to monthly testing was low in the majority of patients (58.2%).
Conclusions: Adherence to bosentan RMMs relevant to minimizing risk of hepatotoxicity either before starting or throughout therapy was low. Our findings could be used as a baseline for monitoring trends in implementation of RMMs over time or to compare performance of various minimization strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2391497 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and Risk Factors of Waterborne and Foodborne Protozoan Pathogens in Kenya: A One Health Perspective.
China CDC Wkly
January 2025
State Key Laboratory of Environmental Aquatic Chemistry, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China.
Intestinal infections affect approximately 450 million people globally, predominantly impacting children and immunocompromised individuals in low- and middle-income countries (LMICs) due to inadequate water, sanitation, and hygiene (WASH) conditions, poverty, malnutrition, and low literacy. In Kenya, the prevalence of intestinal infections is elevated by warm tropical climates and socioeconomic factors. This scoping review evaluates the national prevalence, risk factors, and contamination sources of intestinal protozoa in Kenya, using a One Health approach to synthesize existing data from various human, animal, and environmental studies.
View Article and Find Full Text PDFProton pump inhibitors and all-cause mortality risk among cancer patients.
World J Clin Oncol
January 2025
Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States.
Background: Proton pump inhibitors (PPIs) are widely used, including among cancer patients, to manage gastroesophageal reflux and other gastric acid-related disorders. Recent evidence suggests associations between long-term PPI use and higher risks for various adverse health outcomes, including greater mortality.
Aim: To investigate the association between PPI use and all-cause mortality among cancer patients by a comprehensive analysis after adjustment for various confounders and a robust methodological approach to minimize bias.
Based on critical discourse analysis of Canada's Muskoka Initiative (2010-15), this article outlines how medicalisation contributes to the depoliticisation and technocratisation of global maternal health, while reinforcing patterns of reproductive stratification. By constructing maternal health as a problem of managing medicalised risk, the Muskoka Initiative was able to position family planning as a risk-minimising practice that can improve health by averting pregnancy among populations deemed high risk. Interpreting this construction through the lenses of reproductive justice and biopolitics, I argue that this construction contributes to reproductive stratification and exemplifies how medicalised discourses have replaced overt discourses of population control within development policy, while continuing to discourage reproduction among racialised women in the Global South.
View Article and Find Full Text PDFRisk Estimation of Severe Primary Graft Dysfunction in Heart Transplant Recipients Using a Smartphone.
Rev Cardiovasc Med
January 2025
Cardiac Surgery, Lausanne University Hospital CHUV Lausanne, 1011 Lausanne, Switzerland.
Background: Currently, there are no standardized guidelines for graft allocation in heart transplants (HTxs), particularly when considering organs from marginal donors and donors after cardiocirculatory arrest. This complexity highlights the need for an effective risk analysis tool for primary graft dysfunction (PGD), a severe complication in HTx. Existing score systems for predicting PGD lack superior predictive capability and are often too complex for routine clinical use.
View Article and Find Full Text PDFRecent Developments in Ventricular Assist Device Therapy.
Rev Cardiovasc Med
January 2025
Center for Preclinical Surgical & Interventional Research, The Texas Heart Institute, Houston, TX 77030, USA.
The evolution of left ventricular assist devices (LVADs) from large, pulsatile systems to compact, continuous-flow pumps has significantly improved implantation outcomes and patient mobility. Minimally invasive surgical techniques have emerged that offer reduced morbidity and enhanced recovery for LVAD recipients. Innovations in wireless power transfer technologies aim to mitigate driveline-related complications, enhancing patient safety and quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!